Rohitukine
Rohitukine is an orally active CDK9/T1 inhibitor with an IC50 of 0.3 μM. Rohitukine blocks ATP binding sites of CDK2/A and CDK9/T1, suppresses PPARγ, AKT, mTOR, C/EBPα, SREBP-2, and NF-κB signaling, and increases hepatic LXRα expression. Rohitukine induces S-phase cell cycle arrest, ROS generation, apoptosis, and exhibits anti-inflammatory activity. Rohitukine can be used for the research of leukemia, pancreatic cancer, prostate cancer, breast cancer, CNS cancer, ovarian cancer, lung cancer, dyslipidemia, inflammatory diseases, inflammatory bowel disease, and arthritis.
For research use only. We do not sell to patients.
- CAS No.: 71294-60-5
- Formula: C16H19NO5
- Molecular Weight:305.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
CDK2/A 7.5 μM (IC50) |
CDK9/T1 0.3 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: 5
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 19757855] |
| ASPC1 | GI50 |
21 μM
Compound: 1
|
Cytotoxicity against human AsPC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human AsPC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| BXPC-3 | GI50 |
20 μM
Compound: 1
|
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| Caco-2 | GI50 |
25 μM
Compound: 1
|
Growth inhibition of human Caco2 cells after 48 hrs by MTT assay
Growth inhibition of human Caco2 cells after 48 hrs by MTT assay
|
[PMID: 29370702] |
| DU-145 | GI50 |
26 μM
Compound: 1
|
Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| HCT-116 | IC50 |
8.8 μM
Compound: 5
|
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay
|
[PMID: 19757855] |
| HEK293 | GI50 |
>50 μM
Compound: 1
|
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| HL-60 | GI50 |
10 μM
Compound: 1
|
Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| HL-60 | GI50 |
10 μM
Compound: 1
|
Growth inhibition of human HL60 cells after 48 hrs by MTT assay
Growth inhibition of human HL60 cells after 48 hrs by MTT assay
|
[PMID: 29370702] |
| HL-60 | IC50 |
7.5 μM
Compound: 5
|
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
|
[PMID: 19757855] |
| Hs-578T | GI50 |
20 μM
Compound: 1
|
Cytotoxicity against human Hs578T cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human Hs578T cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| K562 | GI50 |
24 μM
Compound: 1
|
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| LNCaP | GI50 |
30 μM
Compound: 1
|
Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human LNCAP cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| MCF7 | GI50 |
28 μM
Compound: 1
|
Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
Growth inhibition of human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 29370702] |
| MCF7 | IC50 |
>10 μM
Compound: 5
|
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
|
[PMID: 19757855] |
| MDA-MB-231 | GI50 |
13 μM
Compound: 1
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| MDA-MB-468 | GI50 |
17 μM
Compound: 1
|
Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-468 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| MIA PaCa-2 | GI50 |
19 μM
Compound: 1
|
Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| MIA PaCa-2 | GI50 |
19 μM
Compound: 1
|
Growth inhibition of human MIAPaCa2 cells after 48 hrs by MTT assay
Growth inhibition of human MIAPaCa2 cells after 48 hrs by MTT assay
|
[PMID: 29370702] |
| MOLT-4 | GI50 |
12 μM
Compound: 1
|
Cytotoxicity against human MOLT4 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MOLT4 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| NCI-H226 | IC50 |
>10 μM
Compound: 5
|
Cytotoxicity against human NCI-H226 cells after 48 hrs by MTT assay
Cytotoxicity against human NCI-H226 cells after 48 hrs by MTT assay
|
[PMID: 19757855] |
| PANC-1 | GI50 |
22 μM
Compound: 1
|
Cytotoxicity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| PC-3 | GI50 |
19 μM
Compound: 1
|
Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| PC-3 | GI50 |
19 μM
Compound: 1
|
Growth inhibition of human PC3 cells after 48 hrs by MTT assay
Growth inhibition of human PC3 cells after 48 hrs by MTT assay
|
[PMID: 29370702] |
| PSN1 | GI50 |
23 μM
Compound: 1
|
Cytotoxicity against human PSN1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human PSN1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| SF-295 | GI50 |
27 μM
Compound: 1
|
Cytotoxicity against human SF295 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human SF295 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| SF-539 | GI50 |
30 μM
Compound: 1
|
Cytotoxicity against human SF539 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human SF539 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| SNB-75 | GI50 |
22 μM
Compound: 1
|
Cytotoxicity against human SNB75 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human SNB75 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| T47D | GI50 |
24 μM
Compound: 1
|
Cytotoxicity against human T47D cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human T47D cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| THP-1 | GI50 |
28 μM
Compound: 1
|
Cytotoxicity against human THP1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human THP1 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
| U-251 | GI50 |
32 μM
Compound: 1
|
Cytotoxicity against human U251 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human U251 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 27363938] |
In Vitro
Rohitukine (48 h) exhibits selective cytotoxicity against cancer cells, with the highest potency against HL-60 leukemia (GI50 = 10 μM) and Molt-4 leukemia (GI50 = 12 μM), and minimal cytotoxicity against normal fR2 and HEK-293 cell lines (GI50 > 50 μM)[1].
Rohitukine (1-10 μM) induces S-phase cell cycle arrest in HL-60 leukemia cells in a concentration-dependent manner[1].
Rohitukine potently inhibits Cdk9/cyclin T1 (IC50 = 0.3 μM) and weakly inhibits Cdk2/A (IC50 = 7.3 μM) in cell-free biochemical assays[1].
Rohitukine (50 μM) strongly inhibits Dyrk1A, AMPK, and VEGFR kinases in a cell-free profiling assay[1].
Rohitukine (5-20 μM; 2-8 days) inhibits lipid accumulation in 3T3-L1 and C3H10T1/2 adipocytes in a concentration- and time-dependent manner[2].
Rohitukine (20 μM; 48 h-6 days) downregulates pro-adipogenic gene expression (LPL, aP2, SREBP-1c, FAS, PPARγ) and upregulates anti-adipogenic gene expression (Wnt3a, GATA2) in 3T3-L1 adipocytes when treated with 20 μM for 6 days[2].
Rohitukine (20 μM; 15 min-6 days) downregulates late-phase adipogenic protein expression (PPARγ, C/EBPα, aP2, FAS, GLUT4) and inhibits early AKT/mTOR/4EBP signaling in 3T3-L1 adipocytes[2].
Rohitukine (1-20 μM; 24 h) arrests 3T3-L1 preadipocytes in S phase during mitotic clonal expansion in a concentration-dependent manner[2].
Rohitukine (20 μM; 16-24 h) downregulates cell cycle progression proteins (cyclin-D, CDK6, CDK4, cyclin-E, CDK2, C/EBPβ) and stabilizes the CDK inhibitor P27 in 3T3-L1 preadipocytes[2].
Rohitukine (20 μM; 48 h) significantly inhibits 3T3-L1 preadipocyte proliferation during mitotic clonal expansion[2].
Rohitukine (3-100 μM; 24 h) exhibits no cytotoxicity toward J774A.1 macrophage cells, with a cytotoxic IC50 >50 μM[3].
Rohitukine (3-30 μM; 1 h pretreatment, followed by 18 h incubation) dose-dependently inhibits LPS (HY-D1056)-induced nitric oxide production in J774A.1 macrophage cells[3].
Rohitukine (3-30 μM; 18 h) inhibits LPS-induced reactive oxygen species production in J774A.1 macrophage cells[3].
Rohitukine (3-30 μM; 1 h pretreatment, followed by 18 h incubation) inhibits LPS-induced production of IL-1β, TNF-α, IL-6, and PGE2 in J774A.1 macrophage cells[3].
Rohitukine (3-30 μM; 1 h pretreatment, followed by 18 h incubation) dose-dependently inhibits LPS-induced NF-κB transcriptional activity in J774A.1 macrophage cells[3].
Rohitukine (10-30 μM; 1 h pretreatment, followed by incubation) inhibits LPS-induced nuclear translocation of NF-κB in J774A.1 macrophage cells at concentrations of 10 and 30 μM[3].
Rohitukine (10-30 μM; 1 h pretreatment, followed by 2 h incubation) suppresses LPS-induced iNOS and COX-2 protein expression in J774A.1 macrophage cells[3].
Rohitukine (10-30 μM; 1 h pretreatment, followed by 30 min incubation) inhibits LPS-induced activation of the NF-κB pathway by reducing IκB-α phosphorylation and preserving cytosolic NF-κB p65, and inhibits LPS-induced activation of the MAPK pathway by reducing ERK and JNK phosphorylation in J774A.1 macrophage cells[3].
Rohitukine (3-30 μM; 48 h) is non-toxic to primary murine peritoneal macrophages up to 50 μM, and dose-dependently inhibits LPS-induced NO production and release of IL-1β, IL-6, and TNF-α[3].
Rohitukine (0.25-1.0 mM) dose-dependently inhibits growth of five-week-old wild-type Arabidopsis thaliana (Col-0) plants[4].
Rohitukine (0.25-1.0 mM) dose-dependently induces ROS accumulation and increases antioxidant enzyme activity in five-week-old wild-type Arabidopsis thaliana (Col-0) plants[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:3T3-L1, C3H10T1/2 adipocytes
-
Concentration:5; 10; 15; 20 μM
-
Incubation Time:2; 4; 6; 8 days
-
Result:Inhibited lipid accumulation in a concentration-dependent manner.
Significantly reduced lipid accumulation at 5 μM.
Inhibited >80% of MDI-induced lipid accumulation at 20 μM in both cell lines.
Reduced lipid accumulation across all time windows of 20 μM exposure, with maximum inhibition seen with 0-6 days exposure.
Caused a significant reduction in lipid accumulation in 3T3-L1 cells with the shortest 0-2 days exposure.
-
Cell Line:3T3-L1 adipocytes
-
Concentration:20 μM
-
Incubation Time:6 days (gene expression); 48 h (Wnt3a/GATA2 expression)
-
Result:Significantly reduced mRNA expression of pro-adipogenic genes LPL, aP2, SREBP-1c, FAS, and PPARγ.
Caused a nonsignificant decreasing trend in C/EBPα mRNA expression.
Increased mRNA expression of anti-adipogenic transcription factors Wnt3a and GATA2 significantly after 48 h of exposure.
-
Cell Line:3T3-L1 adipocytes
-
Concentration:20 μM
-
Incubation Time:15; 30; 60; 120 min; 2; 4; 6; days
-
Result:Significantly suppressed late-phase protein expression of PPARγ, C/EBPα, aP2, FAS, and GLUT4 on days 2, 4, and 6 of differentiation.
Significantly reduced phosphorylation of AKT (Ser473), mTOR (Ser2448), and 4EBP (Thr37/46) within 2 hours of induction.
-
Cell Line:3T3-L1 preadipocytes
-
Concentration:1; 3; 10; 20 μM
-
Incubation Time:24 hours
-
Result:Caused a concentration-dependent increase in the percentage of cells in S phase.
Induced S-phase arrest during mitotic clonal expansion, with 41.15% of cells in S phase at 20 μM, compared to 19.28% in MDI-only treated cells.
-
Cell Line:3T3-L1 preadipocytes
-
Concentration:20 μM
-
Incubation Time:16; 24 h
-
Result:Reduced protein expression of cyclin-D, CDK6, CDK4, cyclin-E, CDK2, and C/EBPβ at 16 and 24 hours post-induction.
Stabilized expression of the CDK inhibitor P27.
-
Cell Line:J774A.1 macrophage cells
-
Concentration:3; 10; 30; 100 μM
-
Incubation Time:24 h
-
Result:Showed no cytotoxic effects across all tested concentrations, with cell viability remaining near control levels both with and without LPS co-treatment.
Determined a cytotoxic IC50 >50 μM.
-
Cell Line:J774A.1 macrophage cells
-
Concentration:3; 10; 30 μM
-
Incubation Time:1 h pretreatment, followed by 18 h incubation
-
Result:Inhibited LPS-induced release of IL-1β (46%), TNF-α (29%), IL-6 (31%), and PGE2 (48%) at 30 μM compared to the LPS-only control.
Showed inhibitory effects at lower concentrations in a dose-dependent manner.
-
Cell Line:J774A.1 macrophage cells
-
Concentration:10; 30 μM
-
Incubation Time:1 h pretreatment
-
Result:Significantly reduced LPS-induced nuclear translocation of NF-κB, as measured by decreased fluorescent intensity of nuclear NF-κB.
Showed statistically significant inhibition at both 10 μM and 30 μM compared to the LPS-only group.
-
Cell Line:J774A.1 macrophage cells
-
Concentration:10; 30 μM
-
Incubation Time:1 h pretreatment, followed by 2 h incubation
-
Result:Reduced LPS-induced iNOS and COX-2 protein levels by 54% and 68%, respectively, at 30 μM.
Produced significant inhibitory effects on both proteins at 10 μM.
-
Cell Line:J774A.1 macrophage cells
-
Concentration:10; 30 μM
-
Incubation Time:1 h pretreatment, followed by 30 min incubation
-
Result:Downregulated LPS-induced phosphorylation of IκB-α.
Reduced LPS-induced depletion of cytosolic NF-κB p65.
Inhibited LPS-induced phosphorylation of ERK (27% inhibition at 30 μM) and JNK (54% inhibition at 30 μM).
Parmacokinetics
In Vivo
Rohitukine (12.5-50 mg/kg; p.o.; daily; 5 days) dose-dependently inhibits LPS-induced pro-inflammatory cytokine production in mice[3].
Rohitukine (12.5-50 mg/kg; p.o.; single dose) dose-dependently reduces Acetic Acid (HY-Y0319)-induced vascular permeability in mice[3].
Rohitukine (12.5-50 mg/kg; p.o.; single dose) dose-dependently inhibits Carrageenan (HY-125474)-induced paw oedema in rats[3].
Rohitukine (12.5-50 mg/kg; p.o.; single dose) inhibits Carrageenan-induced pleurisy in mice[3].
Rohitukine (12.5-50 mg/kg; p.o.; daily; 14 days) dose-dependently reduces Freund's complete adjuvant-induced arthritis in rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Syrian golden hamster (8-week-old, 100-120 g body weight, dyslipidemia induced by 45% kcal high-fat diet for 10 days)[2]
-
Dosage:50 mg/kg
-
Administration:p.o.; once daily; 7 days
-
Result:Reduced body weight gain significantly compared to HFD and pair-fed groups.
Reduced plasma total cholesterol, triglycerides, LDL-cholesterol, and HDL-cholesterol levels significantly relative to the pair-fed group.
Increased HDL-cholesterol/total cholesterol ratio significantly.
Increased hepatic mRNA expression of liver X receptor α 4-fold.
Reduced LDL receptor, HMG-CoA reductase, and sterol-regulatory element binding protein 2 expression significantly.
Decreased epididymal adipose tissue weight significantly compared to HFD-fed animals.
Reduced protein expression of peroxisome proliferator-activated receptor γ, fatty acid synthase, adipocyte protein 2, and glucose transporter 4 in epididymal adipose tissue.
Reduced lipid accumulation in liver, smaller adipocyte size, and reduced pancreatic lipid droplets compared to HFD-fed hamsters.
-
Animal Model:BALB/c mice (male, 22-25 g, LPS-induced pro-inflammatory cytokine production model)[3]
-
Dosage:12.5; 25; 50 mg/kg
-
Administration:p.o.; daily; 5 days
-
Result:Inhibited LPS-induced IL-1β production by 58%, TNF-α production by 45%, and IL-6 production by 38% at 50 mg/kg.
Significantly reduced IL-1β and TNF-α levels at 25 mg/kg.
Reduced IL-1β, TNF-α, and IL-6 levels compared to the LPS-only group at 12.5 mg/kg.
-
Animal Model:BALB/c mice (male, 22-25 g, acetic acid-induced vascular permeability model)[3]
-
Dosage:12.5; 25; 50 mg/kg
-
Administration:p.o.; single dose
-
Result:Reduced Evans blue leakage by 12.1% at 12.5 mg/kg, 39.3% at 25 mg/kg, and 75.7% at 50 mg/kg compared to the acetic acid control group.
-
Animal Model:Wistar rats (male, 120-140 g, Carrageenan (HY-125474)-induced paw oedema model)[3]
-
Dosage:12.5; 25; 50 mg/kg
-
Administration:p.o.; single dose
-
Result:Suppressed paw oedema by 25% at 12.5 mg/kg, 35% at 25 mg/kg, and 58% at 50 mg/kg compared to the carrageenan control group.
-
Animal Model:BALB/c mice (male, 22-25 g, carrageenan-induced pleurisy model)[3]
-
Dosage:12.5; 25; 50 mg/kg
-
Administration:p.o.; single dose
-
Result:Inhibited pleuritic exudate volume by 59.95% and total leukocyte migration by 86.04% at 50 mg/kg.
Inhibited exudate volume by 61.43% and leukocyte migration by 82.43% at 25 mg/kg.
Inhibited exudate volume by 5.90% and leukocyte migration by 36.82% at 12.5 mg/kg.
-
Animal Model:Wistar rats (male, 120-140 g, Freund's complete adjuvant-induced arthritis model)[3]
-
Dosage:12.5; 25; 50 mg/kg
-
Administration:p.o.; daily; 14 days
-
Result:Inhibited paw oedema by 54%, reduced TNF-α levels by 52%, IL-6 levels by 68%, and IL-1β levels by 71% compared to the arthritic disease control group at 50 mg/kg.
Restored serum SGPT, creatinine, and triglyceride levels to near normal at 50 mg/kg.
Augmented serum SOD, CAT, and GST levels by 96%, 94%, and 98% respectively compared to the arthritic group at 50 mg/kg.
Improved spontaneous motor activity to 39.90 at 50 mg/kg.
Maintained joint architecture with reduced bone erosion on radiographs at 50 mg/kg.
Prevented body weight loss in all treated groups.
Chemical Information
-
CAS No. 71294-60-5
-
Molecular Weight 305.33
-
Formula C16H19NO5
-
SMILES
O=C1C=C(OC2=C1C(O)=CC(O)=C2[C@@H]3[C@@H](CN(CC3)C)O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
-
Collagen-Induced Arthritis
Collagen-induced arthritis (CIA) is an autoimmune murine model of rheumatoid arthritis in which immunization with type II collagen (CII) emulsified in an adjuvant induces a T cell- and autoantibody-driven inflammatory arthritis characterized by synovial hyperplasia, immune cell infiltration, and joint destruction. The model typically relies on genetically susceptible mouse strains (e. g. , DBA/1) and reproduces key features of human rheumatoid arthritis, including anti-collagen immune responses and progressive joint inflammation. Disease onset generally occurs within ~3-4 weeks after immunization, depending on antigen/adjuvant combinations and protocol variation. The immunopathology is driven by adaptive immune activation against CII, leading to systemic and local joint inflammation mediated by pro-inflammatory cytokines and effector immune cells, making CIA a standard preclinical platform for evaluating immunomodulatory and anti-arthritic interventions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Cotton Pellet Granuloma
Cotton pellet granuloma is a classical in vivo chronic inflammation model used to evaluate the anti-inflammatory potential of test substances by measuring their ability to inhibit granuloma tissue formation around an implanted foreign body (cotton pellet) in rodents. The method is based on the biological response to a sterile implanted material, which induces proliferative phase inflammation characterized by fibroblast proliferation and collagen-rich granuloma formation, and the final readout reflects the extent of chronic inflammatory tissue growth surrounding the pellet. In multiple preclinical pharmacological evaluations, inhibition of cotton pellet-induced granuloma formation has been used as an indicator of anti-inflammatory activity in both synthetic and natural product screening contexts.
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
[1]. Kumar V, et al. A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties. Bioorg Med Chem Lett. 2016 Aug 1;26(15):3457-63. [Content Brief]
[2]. Varshney S, et al. Rohitukine inhibits in vitro adipogenesis arresting mitotic clonal expansion and improves dyslipidemia in vivo. J Lipid Res. 2014 Jun;55(6):1019-32. [Content Brief]
[3]. Singh A, et al. Rohitukine inhibits NF-κB activation induced by LPS and other inflammatory agents. Int Immunopharmacol. 2019 Apr;69:34-49. [Content Brief]
[4]. Ahmed S, et al. Exogenously Applied Rohitukine Inhibits Photosynthetic Processes, Growth and Induces Antioxidant Defense System in Arabidopsis thaliana. Antioxidants (Basel). 2022 Aug 3;11(8):1512. [Content Brief]
[5]. Kumara PM, et al. Rohitukine, a chromone alkaloid and a precursor of flavopiridol, is produced by endophytic fungi isolated from Dysoxylum binectariferum Hook.f and Amoora rohituka (Roxb).Wight & Arn. Phytomedicine. 2014 Mar 15;21(4):541-6. [Content Brief]
[6]. Houghton PJ, et al. Further Chromone Alkaloids from Schumanniophyton magnificum. Planta Med. 1987 Jun;53(3):262-4. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)